Original White Feather Rice Intranet
Highlights
Recently, Huluwa issued an announcement that the company's omeprazole enteric-coated capsule was approved for consistency evaluation. According to data from Minenet, the market size of omeprazole enteric-coated capsules in China's three major terminals and six major markets (see the end of the article for statistical scope) will exceed 1 billion yuan in 2023. On July 16, Huluwa reported another good news, and the official website of the State Food and Drug Administration showed that its tenofovir alafenol fumarate tablets were approved for production as imitation Class 4, which was regarded as over-evaluation. Since the beginning of this year, 10 products have passed/deemed to have passed the consistency evaluation.
Omeprazole enteric-coated capsules are indicated for reflux esophagitis, duodenal ulcer, gastric ulcer, non-steroidal anti-inflammatory drug-related gastroduodenal ulcer or erosion, acid-related dyspepsia symptoms, and Zol-Alpha syndrome.
In 2023, it will be the TOP5 internal drug products for the treatment of diseases related to gastric acid secretion in China's three major terminals and six major markets
Source: Minenet Grid Bureau Database
Omeprazole enteric-coated capsule is a national basic drug, a national medical insurance class A and an OTC class A variety, with a sales scale of more than 1 billion yuan in China's three major terminal and six major markets in 2023, and is the TOP4 internal drug product for the treatment of diseases related to gastric acid secretion.
According to the data of Minenet, 94 companies have production approvals for omeprazole enteric-coated capsules, and 17 companies such as Hainan Huluwa Pharmaceutical Group, Jinhua Kangenbei Biopharmaceutical, and CSPC Ouyi Pharmaceutical have been evaluated.
Huluwa said that the company's omeprazole enteric-coated capsule has been evaluated, which is conducive to enhancing the market competitiveness of the drug, has a positive impact on market sales, and has accumulated valuable experience for the company's follow-up products to carry out generic drug consistency evaluation, and the company has invested a total of 12.52 million yuan in research and development expenses for the drug.
Huluwa has previously commented on the product situation
Source: Minenet China Declaration Progress (MED) database
On July 16, Huluwa reported another good news, and the official website of the State Food and Drug Administration showed that its tenofovir alafenol fumarate tablets were approved for production as imitation Class 4, which was regarded as over-evaluation. Since the beginning of this year, 10 Huluwa products have passed/deemed to have passed the consistency evaluation, covering multiple treatment subcategories such as drugs for the treatment of diseases related to gastric acid secretion, drugs for obstructive tracheal diseases, and systemic antiviral drugs. In 2023, omeprazole enteric-coated capsules, tenofovir alafenol fumarate tablets, bromhexine hydrochloride injection, and ibuprofen suspension will be large varieties of 1 billion yuan in China's three major terminal and six major markets.
Source: Company announcements, Minenet database
Note: The statistical scope of "Drug Competition Pattern of China's Three Terminals and Six Major Markets" by Minenet is: urban public hospitals and county-level public hospitals, urban community centers and township health centers, urban physical pharmacies and online pharmacies, excluding private hospitals, private clinics, village clinics, and county and rural pharmacies; The above sales are calculated based on the average retail price of the product at the terminal. If there is any omission, please correct it!